Publications by authors named "M A Campeau"
Background: Cancer control outcomes of lung cancer are hypothesized to be affected by several confounding factors, including tumor heterogeneity and patient history, which have been hypothesized to mitigate the dose delivery effectiveness when treated with radiation therapy. Providing an accurate predictive model to identify patients at risk would enable tailored follow-up strategies during treatment.
Purpose: Our goal is to demonstrate the added prognostic value of including tumor displacement amplitude in a predictive model that combines clinical features and computed tomography (CT) radiomics for 2-year recurrence and survival in non-small-cell lung cancer (NSCLC) patients treated with curative-intent stereotactic body radiation therapy.
Background: Physiotherapy is effective to reduce pain and improve the quality of life of people living with chronic pain. To offer high-quality physiotherapy services, these services must be patient-centred and respond to patients' needs. However, few studies seem to target patients' perceived needs, whereas more studies tend to focus on needs assessed by healthcare experts, which are not always in line with patients' perceived needs.
View Article and Find Full Text PDFPurpose: There is interest in using dual-energy computed tomography (DECT) to evaluate organ function before and after radiation therapy (RT). The purpose of this study (trial identifier: NCT04863027) is to assess longitudinal changes in lung perfusion using iodine maps derived from DECT in patients with lung cancer treated with conventional or stereotactic RT.
Methods And Materials: For 48 prospectively enrolled patients with lung cancer, a contrast-enhanced DECT using a dual-source CT simulator was acquired pretreatment and at 6 and 12 months posttreatment.
Purpose: The use of stereotactic body radiation therapy for tumors in close proximity to the central mediastinal structures has been associated with a high risk of toxicity. This study (NCT03306680) aimed to determine the maximally tolerated dose of stereotactic body radiation therapy for ultracentral non-small cell lung carcinoma, using a time-to-event continual reassessment methodology.
Methods And Materials: Patients with T1-3N0M0 (≤6 cm) non-small cell lung carcinoma were eligible.
Article Synopsis
- * Conducted across six institutions in Canada and Scotland, the research enrolled patients aged 18 and older with specific eligibility criteria and administered SABR with a total dose of 50 Gy in five sessions.
- * Results showed a promising 1-year overall survival rate of 79%, indicating that SABR could be a beneficial treatment despite the patients' high risk of treatment-related toxic effects.